The future lies in "biologics", which unlike small-molecule compounds, cannot be (that) easily copied/manufactured. Initial and continuous capital costs prevent

The future lies in "biologics", which unlike small-molecule compounds, cannot be (that) easily copied/manufactured. Initial and continuous capital costs prevent easy "piracy" and that is where the majority of large-pharam/biotech R&D is headed.